A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer

BACKGROUND: Anlotinib may boost the efficacy of pancreatic cancer (PC) treatment if timely added to the GS regimen (Gemcitabine, Tegafur-gimeracil-oteracil potassium); however, no data has been published. This study evaluated the safety and efficacy of anlotinib in combination with the GS regimen(he...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhan, Gouling, Hu, Jianbing, Da, Shijian, Weng, Jie, Zhou, Chuanyi, Wen, Fang, Liu, Songlian, Fang, Fang, Shen, Erdong, Zhou, Qiang, Luo, Pan, Xu, Min, Zhan, Dahe, Su, Yuqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897321/
https://www.ncbi.nlm.nih.gov/pubmed/36742383
http://dx.doi.org/10.3389/fendo.2023.1110624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897321/
https://www.ncbi.nlm.nih.gov/pubmed/36742383
http://dx.doi.org/10.3389/fendo.2023.1110624

Ejemplares similares